Alzheimer's disease (AD) is a progressive neurodegenerative disorder with a complex
pathogenesis. Senile plaques composed of the amyloid-β (Aβ) peptide in the brain are the …

Recent trials with monoclonal antibodies targeting amyloid-β (Aβ) in Alzheimer's disease
(AD) have sparked a renewed interest in disease-modifying therapies. Despite their …

The amyloid cascade hypothesis for Alzheimer's disease is still alive, although heavily
challenged. Effective anti-amyloid immunotherapy would confirm the hypothesis' claim that …

Over the past 30 years, the majority of (pre) clinical efforts to find an effective therapy for
Alzheimer's disease (AD) focused on clearing the β-amyloid peptide (Aβ) from the brain …

Senile plaques induced by β-amyloid (Aβ) abnormal aggregation and neurofibrillary tangles
(NFT) caused by tau hyperphosphorylation are important pathological manifestations of …

This review analyzes the role of TNF-α and its increase in biological fluids in mild cognitive
impairment, and Alzheimer's disease (AD). The potential inhibition of TNF-α with …

Background Biologic TNF-α inhibitors (bTNFIs) can block cerebral TNF-α in Alzheimer's
disease (AD) if these macromolecules can cross the blood–brain barrier (BBB). Thus, a …

Neuroimmune-triggered neuroinflammation of the central nervous system is emerging as an
important aetiopathogenic factor for multiple neurological disorders, including depression …

Introduction Alzheimer's disease (AD) is a major global public health challenge. To date, no
treatments have been shown to stop the underlying pathological processes. The cerebral …

Alzheimer's disease (AD) is a progressive neurodegenerative disease representing the most
common type of dementia in older adults. The major risk factors include increased age …